316 related articles for article (PubMed ID: 28521156)
21. Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
Xu S; Xu T; Zhang L; Zhang Z; Luo J; Liu Y; Lu X; Tu Z; Ren X; Ding K
J Med Chem; 2013 Nov; 56(21):8803-13. PubMed ID: 24124898
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of novel 1
Liu J; Wen Y; Gao L; Gao L; He F; Zhou J; Wang J; Dai R; Chen X; Kang D; Hu L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):72-84. PubMed ID: 31682465
[TBL] [Abstract][Full Text] [Related]
23. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors.
Ran K; Zeng J; Wan G; He X; Feng Z; Xiang W; Wei W; Hu X; Wang N; Liu Z; Yu L
Eur J Med Chem; 2021 Aug; 220():113499. PubMed ID: 33940465
[TBL] [Abstract][Full Text] [Related]
25. Pemigatinib: First Approval.
Hoy SM
Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
[TBL] [Abstract][Full Text] [Related]
27. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
28. Discovery of 4,6-Disubstituted Pyrimidine Derivatives as Novel Dual VEGFR2/FGFR1 Inhibitors.
Zhang JY; Xue WJ; Wang M; Li W; Dong R; Li MT; Sun LP
Chem Biodivers; 2021 May; 18(5):e2100095. PubMed ID: 33829649
[TBL] [Abstract][Full Text] [Related]
29. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
Jin Q; Zhang D; Gao M; Jiang C; Zhang J
Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.
Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
[TBL] [Abstract][Full Text] [Related]
31. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo.
Chen CH; Liu YM; Pan SL; Liu YR; Liou JP; Yen Y
Oncotarget; 2016 May; 7(18):26374-87. PubMed ID: 27029060
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
33. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of N-phenylthieno[2,3-d]pyrimidin-4-amines as inhibitors of FGFR1.
Gryshchenko AA; Bdzhola VG; Balanda AO; Briukhovetska NV; Kotey IM; Golub AG; Ruban TP; Lukash LL; Yarmoluk SM
Bioorg Med Chem; 2015 May; 23(9):2287-93. PubMed ID: 25817240
[TBL] [Abstract][Full Text] [Related]
36. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis, and Biological Evaluation of C-2 Substituted 3Hthieno[ 2,3-d]pyrimidin-4-one Derivatives as Novel FGFR1 Inhibitors.
Guo P; Xie Z; Zhang H; Zhang Z; Han C; Cheng D; Lin D; Zhang Y; Wang X; Guo X; Ye F
Med Chem; 2017; 13(8):753-760. PubMed ID: 28641527
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors.
Xun Q; Zhang Z; Luo J; Tong L; Huang M; Wang Z; Zou J; Liu Y; Xu Y; Xie H; Tu ZC; Lu X; Ding K
J Med Chem; 2018 Mar; 61(6):2353-2371. PubMed ID: 29499108
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, anticancer evaluation and molecular docking of new benzothiazole scaffolds targeting FGFR-1.
Abd El-Meguid EA; Mohi El-Deen EM; Moustafa GO; Awad HM; Nossier ES
Bioorg Chem; 2022 Feb; 119():105504. PubMed ID: 34836644
[TBL] [Abstract][Full Text] [Related]
40. Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
Ahmed EY; Elserwy WS; El-Mansy MF; Serry AM; Salem AM; Abdou AM; Abdelrahman BA; Elsayed KH; Abd Elaziz MR
Bioorg Med Chem Lett; 2021 Sep; 48():128258. PubMed ID: 34246754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
